India reported 47,029 coronavirus cases and 509 deaths in the last 24 hours. With this the country's overall caseload rose to 3.28 crore and the death toll increased to 4.39 lakh.
Hyderabad-based Biological E Limited was granted permission by the Drug Controller General of India (DCGI) to conduct Phase 2 and 3 clinical trials for Corbevax on children. The trial will be on children between 5 and 18 years of age with certain conditions.
‘India reported 47,029 coronavirus cases and 509 deaths in the last 24 hours. With this the country's overall caseload rose to 3.28 crore and the death toll increased to 4.39 lakh.’
The permission was given on Wednesday after the recommendation from the Subject Expert Committee. The trial will be conducted in ten locations across the country.
The government has made an advance payment of Rs 1,500 crore to Biological E for the 30 crore vaccines.
Meanwhile, the trials of Bharat Biotech's Covaxin Covid-19 vaccine for phases 2 and 3 for children are underway, and its result is expected in September.
The Zydus Cadila's needle-free Covid-19 vaccine ZyCoV-D has already received emergency use authorisation (EUA) to inoculate children in the age group of 12-18. It is expected to be administered from the first week of October.
Advertisement
Meanwhile, India reported 47,029 coronavirus cases and 509 deaths in the last 24 hours. With this the country's overall caseload rose to 3.28 crore (3,28,57,937) and the death toll increased to 4.39 lakh (4,39,529).
Advertisement
Source-IANS